HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development

Effective targeting of the human epidermal growth factor receptor 2 (HER2) has changed the natural history of HER2 overexpressing (HER2+) metastatic breast cancer. The initial success of trastuzumab improving time to progression and survival rates led to the clinical development of pertuzumab, ado-t...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, J C, Jhaveri, K, Esteva, F J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229628/
https://www.ncbi.nlm.nih.gov/pubmed/25025958
http://dx.doi.org/10.1038/bjc.2014.388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229628/
https://www.ncbi.nlm.nih.gov/pubmed/25025958
http://dx.doi.org/10.1038/bjc.2014.388

Ejemplares similares